Although ASO-mediated exon-skipping has received clinical approval for the treatment of DMD, they remain limited in their ability to increase partially functional dystrophin levels in muscle and have little effect on cardiac tissues [111]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.